Regulation of prostate cancer immunity-related genes in PC3 prostate cancer cells by ETS-1

Adler,David; Lindstrot,Andreas; Buettner,Reinhard; Wernert,Nicolas

doi:10.3892/ol.2011.509

Regulation of prostate cancer immunity-related genes in PC3 prostate cancer cells by ETS-1

Authors:
- David Adler
- Andreas Lindstrot
- Reinhard Buettner
- Nicolas Wernert
View Affiliations

Affiliations: Institute of Pathology, University Hospital Bonn, D-53127 Bonn, Germany
Published online on: December 2, 2011 https://doi.org/10.3892/ol.2011.509
Pages: 513-516

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is one of the most prevalent forms of cancer affecting males worldwide, and knowledge of the immune defenses involved in PCa remains incomplete. Since the identification of immunity-related genes may have enormous implications for the understanding of PCa immunology, we recently reported the identification of immunity-related genes in PCa tissues and found potential binding sites for the ETS family prototype, ETS-1, in the majority of genes identified. Therefore, as a continuation of our previous study, we investigated whether ETS-1 regulates these genes in an in vitro PCa cell line model, PC3 cells. We specifically blocked ETS-1 in PC3 cells by transfection with an ETS-1 inverse antisense expression vector or a mock control vector. We then assessed the effect of the blockade on the expression of the recently identified PCa immunity-related genes using a comprehensive oligo gene expression microarray analysis. The results showed that ETS-1 is involved in the activation or repression of the recently identified immunity‑related genes in PCa. These findings provide insights into the regulation of immunity-related genes in PCa, and emphasize the importance of ETS-1 in prostate cancer immunology.

View Figures

View References

1	Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nature Rev. 8:497–511. 2008.PubMed/NCBI
2	Hsu DS, Kim MK, Balakumaran BS, et al: Immune signatures predict prognosis in localized cancer. Cancer Invest. 28:765–773. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
4	Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A and Thompson TC: Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60:5857–5861. 2000.PubMed/NCBI
5	Vesalainen S, Lipponen P, Talja M and Syrjanen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 30A:1797–1803. 1994. View Article : Google Scholar
6	Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L and Davis ID: Prostate cancer immunology - an update for Urologists. BJU Int. 107:1046–1051. 2010. View Article : Google Scholar : PubMed/NCBI
7	Shaikhibrahim ZLA, Ellinger J, Rogenhofer S, Buettner R and Wernert N: Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. Int J Mol Med. 28:799–807. 2011.PubMed/NCBI
8	Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
9	Gallant S and Gilkeson G: ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp (Warsz). 54:149–163. 2006. View Article : Google Scholar : PubMed/NCBI
10	Alipov G, Nakayama T, Ito M, et al: Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 46:202–208. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rothhammer T, Hahne JC, Florin A, et al: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 61:118–128. 2004. View Article : Google Scholar : PubMed/NCBI
12	Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F and Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage- independent growth. Oncogene. 24:5384–5388. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sahin A, Vercamer C, Kaminski A, et al: Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. Int J Oncol. 34:377–389. 2009.
14	Shaikhibrahim Z, Langer B, Lindstrot A, et al: Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells. Oncol Rep. 25:1125–1129. 2011.PubMed/NCBI
15	Shaikhibrahim Z, Lindstrot A, Langer B, Buettner R and Wernert N: Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade. Int J Mol Med. 27:811–819. 2011.
16	Chen CA and Okayama H: Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. BioTechniques. 6:632–638. 1988.PubMed/NCBI
17	Liu AY, Roudier MP and True LD: Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 165:1543–1556. 2004. View Article : Google Scholar : PubMed/NCBI
18	Milde T, Oehme I, Korshunov A, et al: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 16:3240–3252. 2010. View Article : Google Scholar : PubMed/NCBI
19	Moreno DA, Scrideli CA, Cortez MA, et al: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol. 150:665–673. 2010. View Article : Google Scholar : PubMed/NCBI
20	Satterwhite E, Sonoki T, Willis TG, et al: The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 98:3413–3420. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kosari F, Asmann YW, Cheville JC and Vasmatzis G: Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev. 11:1419–1426. 2002.PubMed/NCBI
22	Bjartell AS, Al-Ahmadie H, Serio AM, et al: Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 13:4130–4138. 2007. View Article : Google Scholar : PubMed/NCBI
23	Mollenhauer J, Wiemann S, Scheurlen W, et al: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours. Nat Genet. 17:32–39. 1997.PubMed/NCBI
24	Mollenhauer J, Herbertz S, Holmskov U, et al: DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res. 60:1704–1710. 2000.PubMed/NCBI
25	Kim HS, Han HD, Armaiz-Pena GN, et al: Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 17:1713–1721. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yoo KH, Kim SK, Chung JH and Chang SG: Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia. Asian J Androl. 12:690–696. 2010.PubMed/NCBI
27	Sung HJ, Ahn JM, Yoon YH, et al: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 10:1383–1395. 2011. View Article : Google Scholar : PubMed/NCBI
28	Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, et al: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem. 58:1015–1023. 2010. View Article : Google Scholar : PubMed/NCBI